Local IFN-γ therapy of HPV16-associated tumours

Folia Biologica

Volumn 49, Issue 1, 2003, Pages 26-32

  Mikyšková, Romana ^b   Bieblova J ^b   Simova J ^b   Indrova M ^b   Jandlova T ^b   Vonka, V ^a   Smahel M ^a   Bubenik J ^b   Mendoza, L ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

HPV16; IFN ; MHC class I; Residual tumour disease

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER INFILTRATION; CANCER INHIBITION; CANCER TRANSPLANTATION; CARCINOMA CELL; CELL POPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; IN VIVO STUDY; LUNG METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; REVIEW; SUBCUTANEOUS TISSUE TUMOR; TUMOR RECURRENCE; TUMOR VOLUME; UPREGULATION; WART VIRUS;

ANIMALIA; HUMAN PAPILLOMAVIRUS TYPES; PAPOVAVIRIDAE;

EID: 0037281208     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, K. H., Reaman, G. H., Tosato, G. (1995) Human interferon-inducible protein 10 is a potent inducer of angiogenesis in vivo. J. Exp. Med. 182, 155-162.
2. Brunda, M. J., Luistro, L., Hendrzack, J. A., Fountolakis, M., Garotta, G., Gateley, M. K. (1995) Role of IFN-γ in mediating the antitumor efficacy of IL-12. J. Immunother. 17, 71-77.
3. Bubeník, J., Šímová, J., Hájková R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int. J. Oncol. 14, 593-597.
4. Bubeník, J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2002) Interleukin 2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine, in press.
5. Connor, M. E., Stern, P. L. (1990) Loss of MHC class I expression in cervical carcinomas. Int. J. Cancer 46,1029-1034.
6. Garrido, F., Ruiz-Cabello, F., Cabrera, I., Perez-Villaz, J. J., Lopez-Botet, M., Duggan-Keen, M., Stern, P. L. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
7. Hicklin, D. J., Marincola, F. M., Ferrone, S. (1999) HLA class I antigen downregulation in human cancers: T cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186.
8. Indrová, M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
9. + tumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
10. - tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines, Int. J. Oncol., in press.
11. Mikyšková, R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of the lung metastases. Clin. Exp. Metastasis 18, 581-587.
12. Segal, J. G., Lee N. C., Tsung Y. L., Norton J. A., Tsung K. (2002) The role of IFN-γ in rejection of established tumors by IL-12: source of production and target. Cancer Res. 62, 4696-4703.
13. Strasly, M., Cavallo, F., Geuna, M., Mitola, S., Colombo, M. P., Forni, G., Bussolino, F. (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166, 3890-3899.
14. - negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
15. Šmahel, M., Šíma, P., Ludvíková, V., Marinov, I., Pokorná, D., Vonka, V. Immunization with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine, in press.
16. Vlk, V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.